Welcome to LookChem.com Sign In|Join Free
  • or
2H-Benzimidazol-2-one,1,3-dihydro-1-methyl-7-nitro-(9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

24133-87-7

Post Buying Request

24133-87-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

24133-87-7 Usage

Physical properties

yellow crystalline powder

Uses

synthesis of pharmaceuticals and organic compounds
Handle with care due to potential hazards and risks

Check Digit Verification of cas no

The CAS Registry Mumber 24133-87-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,1,3 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 24133-87:
(7*2)+(6*4)+(5*1)+(4*3)+(3*3)+(2*8)+(1*7)=87
87 % 10 = 7
So 24133-87-7 is a valid CAS Registry Number.

24133-87-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-methyl-7-nitrobenzimidazol-2-one

1.2 Other means of identification

Product number -
Other names 1-Methyl-7-nitro-benzimidazolon-(2)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:24133-87-7 SDS

24133-87-7Downstream Products

24133-87-7Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

-

, (2021/06/26)

The present invention provides compounds, compositions thereof, and methods of using the same.

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

-

, (2021/09/04)

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

MDM2 DEGRADERS AND USES THEREOF

-

, (2021/09/26)

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

MERTK DEGRADERS AND USES THEREOF

-

, (2020/01/31)

The present invention provides compounds, compositions thereof, and methods of using the same.

CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE

-

, (2020/09/12)

Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral E1A binding protein of 300kDa (P300) ligand (CBP/P300 ligand) conjugated

COMPOUNDS AND METHODS OF TREATING CANCERS

-

, (2020/10/20)

This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of ce

IRAK DEGRADERS AND USES THEREOF

-

, (2021/01/23)

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

CRBN LIGANDS AND USES THEREOF

-

, (2019/04/16)

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

o-Nitroaniline derivatives - 13. Reactions of N-(o-nitroaryl)sarcosine esters with bases

Collins,McFarlane,Mackie,Smith

, p. 7887 - 7898 (2007/10/02)

The title reactions give 1-hydroxy-4-methylquinoxaline-2,3-diones (4) together with a variety of mono- and bi-cyclic byproducts. All of these may result from a common intermediate, viz. a 1-hydroxy-4-methyl-3,4-dihydro-1H-2,1,4-benzoxadiazine-3-carboxylat

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 24133-87-7